Search alternatives:
larger decrease » marked decrease (Expand Search)
less decrease » we decrease (Expand Search), levels decreased (Expand Search), largest decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
less decrease » we decrease (Expand Search), levels decreased (Expand Search), largest decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
-
761
-
762
-
763
<b> </b> Rate of brain weight to body weight in different experimental groups. AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate....
Published 2025“…AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate. …”
-
764
Survival function analysis of mortality for Viral load status and Treatment Interruption status.
Published 2025Subjects: -
765
-
766
-
767
Survival function analysis of treatment Interruption for Viral load status and BMI status.
Published 2025Subjects: -
768
Survival function analysis of viral suppression for BMI status and Treatment Interruption status.
Published 2025Subjects: -
769
-
770
-
771
-
772
-
773
-
774
-
775
-
776
Survival function analysis for LTFU according to Viral Load status and BMI status.
Published 2025Subjects: -
777
-
778
Annual incidence rate per 100 person-years trend for ART treatment outcomes.
Published 2025Subjects: -
779
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
780